Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
To assess the symptomatic outcome following transurethral prostatectomy (TURP), alpha-blockade and placebo treatment in uncomplicated benign prostatic hyperplasia (BPH), 260 patients were evaluated with the recently formulated Danish Prostatic Symptom Score (DAN-PSS-1) system: 205 were randomized to either the selective alpha-blocker alfuzosin or placebo and 55 underwent TURP. Following TURP, the DAN-PSS-1 score was reduced by 80% after 6-10 weeks (visit 2) and by 100% after 12-16 weeks (visit 3). In the alfuzosin group the corresponding reductions were 40% and 65% (p < 0.02 vs. placebo). In the placebo group the reduction was 25% at visit 2, with no further fall demonstrated thereafter. During alfuzosin treatment the bother score (impact of symptoms on quality of life) fell more than the symptom score. During placebo treatment there was no reduction in symptom score. We conclude that the DAN-PSS-1 questionnaire sensitively identifies clinically important responses to treatment of BPH.
Hansen
B J
BJ
Department of Urology, Bispebjerg Hospital, Denmark.
Flyger
H
H
Mortensen
S
S
Mensink
H J
HJ
Meyhoff
H H
HH
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000628:therapy*; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*; D001748:Urinary Bladder Neck Obstruction / Q000175:diagnosis / Q000628:therapy*; D014555:Urination Disorders / Q000175:diagnosis / Q000628:therapy; D014563:Urodynamics / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin